share_log

遠大醫藥:本集團全球創新放射性核素偶聯藥物ITM-11 在中國獲批開展III期臨床研究

GRANDPHARMA: THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA

香港交易所 ·  Mar 24 06:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more